title: Edaravone offers neuroprotection for acute diabetic stroke patients.
abstract: BACKGROUND
  Edaravone, a novel free-radical scavenger, has been shown to alleviate cerebral ischemic injury and protect against vascular endothelial dysfunction. However, the effects of edaravone in acute diabetic stroke patients remain undetermined.
  
  
  METHODS
  A randomized, double-blind, placebo-controlled study was performed to prospectively evaluate the effects of edaravone on acute diabetic stroke patients admitted to our hospital within 24 h of stroke onset. The edaravone group received edaravone (30 mg twice per day) diluted with 100 ml of saline combined with antiplatelet drug aspirin and atorvastatin for 14 days. The non-edaravone group was treated only with 100 ml of saline twice per day combined with aspirin and atorvastatin. Upon admission, and on days 7, 14 post-stroke onset, neurological deficits and activities of daily living were assessed using the National Institutes of Health Stroke Scale (NIHSS) and the Barthel Index (BI), respectively. The occurrence of hemorrhage transformation, pulmonary infection, progressive stroke and epilepsy was also evaluated on day 14 post-treatment.
  
  
  RESULTS
  A total of 65 consecutive acute diabetic stroke patients were enrolled, of whom 35 were allocated to the edaravone group and 30 to the non-edaravone group. There was no significant group difference in baseline clinical characteristics, but mean NIHSS scores were lower (60 %), and BI scores were 1.7-fold higher, in edaravone-treated patients vs. controls on day 14. Furthermore, the incidence of hemorrhage transformation, pulmonary infection, progressive stroke and epilepsy was markedly reduced in the edaravone vs. non-edaravone group.
  
  
  CONCLUSIONS
  Edaravone represents a promising neuroprotectant against cerebral ischemic injury in diabetic patients.
authors.affiliation: Department of Neurology, Shanghai Eighth Hospital, Jiangsu University, 8 Caobao Road, Shanghai, 200235, China.
authors.forename: J
authors.initials: J
authors.lastname: Zheng
authors.affiliation: Department of Neurology, Shanghai Eighth Hospital, Jiangsu University, 8 Caobao Road, Shanghai, 200235, China. cxwp65@163.com.
authors.forename: X
authors.initials: X
authors.lastname: Chen
mesh_terms: D000203:Activities of Daily Living; D000368:Aged; D000369:Aged, 80 and over; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy; D004311:Double-Blind Method; D000077553:Edaravone; D005260:Female; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D016166:Free Radical Scavengers; D018696:Neuroprotective Agents; D010975:Platelet Aggregation Inhibitors; D000077553:Edaravone; D000983:Antipyrine
keywords: Diabetic stroke; Edaravone; Neuroprotection